AML Treatment Considerations for Oncology Nursing: On-Demand Webcast
  • CE

Review this archived presentation by a nursing expert on the optimal management of patients with acute myeloid leukemia
person default
Elizabeth S. Kaled, NP
Ayelet Nelson, ANP-BC
Registered Nurses: 1.0 Nursing contact hour
Released: May 15, 2020 Expiration: May 14, 2021
Multimedia AML Treatment Considerations for Oncology Nursing: On-Demand Webcast
This program is divided into short segments which you can review from the Activity landing page.
The Evolving AML Treatment Landscape: Considerations for Oncology Nursing (2 minutes)
Welcome to this program examining the best-practice nursing strategies for the care of patients with acute myeloid leukemia.
Launch The Evolving AML Treatment Landscape: Considerations for Oncology Nursing (2 minutes)
Diagnosis and Management of Newly Diagnosed AML (24 minutes)
Review nursing recommendations for the diagnosis and initial treatment considerations for patients with acute myeloid leukemia, including 7+3 and CPX-351.
Launch Diagnosis and Management of Newly Diagnosed AML (24 minutes)
Newly Diagnosed AML: Targeted Therapies (12 minutes)
Explore key nursing points for additional treatment options for newly diagnosed AML, including venetoclax combinations, gemtuzumab ozogamicin, and FLT3 and IDH1 inhibitors.
Launch Newly Diagnosed AML: Targeted Therapies (12 minutes)
Relapsed/Refractory AML: Considerations and Challenges (2 minutes)
Examine the best nursing strategies for patients with relapsed/refractory AML.
Launch Relapsed/Refractory AML: Considerations and Challenges (2 minutes)
Managing Common Adverse Events in AML (7 minutes)
Review nursing strategies for optimal adverse event management for patients with AML.
Launch Managing Common Adverse Events in AML (7 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the phases of AML therapy (including treating leukostasis, and induction/consolidation therapy)
  • Outline individualized management plans for AML based on disease, patient, and agent characteristics
  • Identify recommendations for cytogenetic and molecular biomarkers that are used to select therapy in AML
  • Review newer approved and investigational targeted agents used along with chemotherapy for improved outcomes
  • Identify strategies for addressing quality-of-life concerns, supportive care needs for patients with AML
  • Discuss the management of treatment-related adverse events for patients with AML

Acknowledgements

This activity is jointly provided by Global Education Group and MCM Education, in partnership with Clinical Care Options, LLC.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Supported by an educational grant from
Jazz Pharmaceuticals, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth S. Kaled, NP, has no relevant conflicts of interest to report.
Ayelet Nelson, ANP-BC

Outpatient Leukemia Nurse Practitioner
Division of Hematology/Oncology
Weill Cornell Medicine
New York, New York

Ayelet Nelson, ANP-BC, has no relevant conflicts of interest to report.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Ashley Marostica, RN, MSN                                                    Nothing to disclose

Andrea Funk                                                                              Nothing to disclose

Liddy Knight                                                                              Nothing to disclose

Ashley Cann                                                                              Nothing to disclose

Target Audience

The proposed learning activities are intended for oncology nurses, nurse practitioners, and other healthcare providers who manage and care for patients with AML, including nursing professionals affiliated with community and academic hospitals, oncology practices, or healthcare systems.

Goal

The goal of this continuing education activity is to enhance knowledge and clinical competency among oncology nurses in the nursing care of patients with AML.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 15, 2020, through May 14, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Living slideset on optimal management of CLL during the COVID-19 pandemic will be continually up-to-date as the situation evolves and new data emerge

Jacqueline Barrientos, MD, MS Nicole Lamanna, MD John Pagel Headshot John Pagel, MD, PhD person default Jacob D. Soumerai, MD Released: July 2, 2020

Gain key clinical insights quickly with this short slideset from CCO on CAR T-cell therapy for hematologic malignancies.

Michael R. Bishop, MD Daniel J. DeAngelo, MD, PhD Noopur Raje, MD Released: June 30, 2020

Mary Jo Fidler, MD discusses key data in lung malignancies from ASCO 2020 and optimization of therapeutic benefit through management of cancer cachexia syndrome

person default Mary Jo Fidler, MD Released: June 30, 2020

John L. Marshall, MD discusses key data in GI malignancies from ASCO 2020 and optimizing therapeutic benefit through management of cancer cachexia

John L. Marshall, MD Released: June 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?